Agilent Technologies vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Santa Clara analytical instruments (NYSE: A) at $6.95B FY2025 revenue; Q4 +9.4% recovery from pharma destocking, LC-MS/gas chromatography leader for drug dev and food safety competing with Waters and Thermo Fisher.
About
Agilent Technologies, Inc. is a Santa Clara, California-based life sciences, diagnostics, and applied chemical analysis instruments company — publicly traded on the New York Stock Exchange (NYSE: A) as an S&P 500 Health Care component — designing, manufacturing, and supporting analytical instruments, consumables, software, and services for pharmaceutical, biopharmaceutical, food safety, environmental, clinical, and academic laboratory applications through approximately 17,000 employees worldwide. In fiscal year 2025 (ending October 2025), Agilent reported full-year revenue of $6.95 billion, with Q4 FY2025 revenue of $1.86 billion (+9.4% reported, +7.2% core growth) — accelerating from the prior year's market correction when the pharmaceutical and biopharma industry destocked lab consumables following the COVID-era inventory surge. The Life Sciences and Diagnostics Markets Group delivered Q4 FY2025 revenue of $755 million (+15% reported, +11% core), reflecting a robust recovery in pharmaceutical R&D laboratory spending. Founded in 1999 as a spinoff from Hewlett-Packard's analytical instruments division (carrying forward HP's tradition of precision measurement instruments dating to 1939), Agilent is organized around three segments: Life Sciences & Applied Markets (liquid chromatography, mass spectrometry, gas chromatography systems for drug development and food/environmental testing), Diagnostics & Genomics (pathology reagents, next-generation sequencing, FISH probes for cancer diagnostics), and Agilent CrossLab (instrument services, calibration, laboratory informatics, and consumables replacement).
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.